Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections
Alison Blackman, Praneeth Jarugula, David P. Nicolau, Sai Ho Chui, Manjari Joshi, Emily L. Heil, Mathangi Gopalakrishnan
Abstract
/MIC targets, for noncirrhotic patients at 140 kg, the PTA with standard linezolid doses was 100%, 98.8%, 34.1%, and 0% for MICs of 0.5, 1, 2, and 4 mg/liter, respectively. In conclusion, target attainment of ≥90% is not achieved with standard linezolid doses for noncirrhotic patients ≥140 kg with MICs of ≥2 mg/liter. This study adds to accumulating evidence that standard linezolid doses may not be adequate for all patients.
Topics & Concepts
Critically illLinezolidPharmacokineticsMedicineIntensive care medicineSoft tissueInternal medicineSurgeryStaphylococcus aureusBiologyGeneticsBacteriaVancomycinAntimicrobial Resistance in StaphylococcusAntibiotics Pharmacokinetics and EfficacyBacterial Identification and Susceptibility Testing